Morgan et al. BMC Cancer 2010, 10:89 http://www.biomedcentral.com/1471-2407/10/89 Page 6 of 9 Figure 5 PARP cleavage induced by HXR9. Lysates of CXR9-treated and HXR9-treated SK-OV3 cells were probed with an anti-PARP antibody. A lysate of etoposide treated HL60 leukaemia cells was included as a positive control. Lane 1 - untreated HL60 cells, Lane 2- etoposide treated HL60 cells, Lane 3 - CXR9 treated SK-OV3 cells, Lane 4 - HXR9 treated SK-OV3 cells. ‘PARP’ - position of full length PARP protein (116kDa), ‘PARP (c)’ - position of cleaved PARP (85kDa). Beta-actin is included as a loading control. Figure 6 c-Fos expression is elevated after treatment with HXR9. SK-OV3 and OV-90 cells were incubated for 24 hours with 120 μM HXR9 or CXR9 and cFos expression was analysed by RT-QPCR. RNA was also extracted from SK-OV3 tumours excised from mice treated twice weekly with HXR9 (10 mg/Kg)iv, after an initial dose of 100 mg/Kg iv on day 3. Results are presented as a ratio with beta-actin expression (x1000). A very high increase in transcription of c-Fos in HXR9 treated SK-OV3 cells and tumours was observed. Error bars represent the standard error of the mean for three independent experiments (cell lines) or for three tumours (in vivo model).